The announcement describes a research and infrastructure program rather than the results of a clinical trial. Its central premise is that many AI algorithms have been proposed for aging and dementia care, but relatively few have undergone the rigorous evaluation, safe implementation and continuous monitoring required for routine practice. Duke AITC-AIGE will support pilot grants, data science resources, implementation assistance, governance tools and methods for assessing whether AI systems improve real-world outcomes for older adults and people with Alzheimer’s disease and related dementias.

Funding will provide about $5 million annually to the center, including approximately $4 million each year for research projects across the country. At least 80% of that research funding will be reserved for Alzheimer’s disease and related dementias, with the remainder supporting broader aging research. The nationwide program is designed to extend AI expertise beyond major academic medical centers and make support accessible to investigators at smaller institutions, community organizations, patients and caregivers who may have ideas for useful tools but lack the infrastructure required to build and test them.

The center is housed within the Duke Clinical and Translational Science Institute and is organized around three components. Juliessa Pavon, an associate professor in Duke’s Division of Geriatrics, leads the Administrative Core. Rishi Kamaleswaran, an associate professor of surgery and anesthesiology, leads the Clinical Implementation and Data Science Core. Sheng Luo, a professor of biostatistics and bioinformatics, leads the Research Innovation Core. Duke said the collaboration reflects the university’s capabilities in geriatrics, dementia research, translational science and responsible AI oversight.

Potential applications include detecting early cognitive decline by analyzing speech, behavior or data from wearable devices; identifying risks such as falls or wandering; supporting medication optimization and deprescribing; and helping caregivers monitor systems or access personalized guidance. These uses remain possibilities that require evaluation rather than established clinical benefits. The center’s role will include helping researchers determine which systems work in real-world settings, whether they improve outcomes and quality of life, and where their performance is insufficient or unsafe.

Transparency is a major focus of the initiative. Researchers and organizations will be able to develop and adapt model cards, standardized documents that summarize a tool’s intended purpose, training data, test performance, areas of strong performance and settings in which it may be less reliable. The cards can also document potential biases, limitations and appropriate uses. Pavon compared the idea to the nutritional information on food packaging, saying that clinicians and health systems should have a clear understanding of an AI tool’s risks and benefits before using it in a particular situation.

The Research Innovation Core will develop statistical and AI methods to identify performance limitations, investigate their causes and improve the reliability and generalizability of aging-related systems. Its work is particularly important because an AI model that performs well in a controlled research dataset may behave differently when applied to a new hospital, community or patient population. The press release does not report measured improvements from these methods; instead, it presents their development and testing as the center’s planned contribution to producing AI systems that can be assessed more systematically.

Duke will also develop the NeuroAI secure analytics and evaluation platform, which is intended to bring together medical records, brain images, laboratory results and genetic information. The platform will provide shared data and standardized methods for studying aging and dementia, developing AI tools and evaluating them. Duke said this common infrastructure could reduce the time, cost and specialized technical knowledge required to develop and test systems, making it easier for community researchers, smaller institutions, patients and caregivers to participate in innovation rather than leaving that work concentrated at large academic centers.

Beyond technical development, the center plans to provide national pilot funding and expertise in AI evaluation, data science, implementation, ethics, governance and stakeholder engagement. Its resources are intended to be reusable by investigators and organizations that are not part of a major academic AI center. Safety monitoring, implementation tools and standardized evaluation methods will sit alongside the research portfolio, reflecting the program’s emphasis that clinical adoption requires evidence about performance, oversight and continued operation in real environments.

The five-year goal is not simply to produce more algorithms, Pavon said, but to establish a clearer and reproducible route from innovation to safe, meaningful benefit. Success after five years would mean that researchers and health systems have better ways to determine which AI tools should enter practice, how they should be monitored and whether they support independence, care delivery, caregiver support and quality of life for older adults. The initiative therefore joins technical AI research with evaluation and governance infrastructure intended to address a central obstacle in translating aging-related AI from promising prototypes into dependable health tools.

Subject of Research: A national research infrastructure initiative for trustworthy artificial intelligence in aging and dementia care.

Article Title: Duke launches national hub to advance trustworthy AI for aging and dementia care

Article References: Duke launches national hub to advance trustworthy AI for aging and dementia care. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: Duke University, trustworthy AI, aging care, dementia, Alzheimer’s disease, AI evaluation, clinical implementation, responsible AI, NeuroAI, National Institute on Aging, Duke, launches

The reference was developed by a working group under the Biomedical and Health Standards Committee of the Singapore Standards Council. Enterprise Singapore administers the council, while the Duke-NUS Centre of Regulatory Excellence–Standards Development Organisation supported the work. The group included representatives from public healthcare institutions, ethics committees, industry and regulatory bodies. TR 151 explains how ISO 14155:2026, the international standard for good clinical practice in medical device investigations, should be applied when planning and reviewing device studies in Singapore.

Singapore’s existing clinical-trial guidance was largely designed with medicines in mind and offered limited direction on device-specific considerations, according to the announcement. As a result, applications for medical device studies could vary widely in content and depth, leaving innovators without a shared understanding of what ethics committees expected. Inconsistent applications could trigger repeated requests for clarification, imposing particular burdens on start-ups and small and medium-sized enterprises with limited regulatory resources.

TR 151 seeks to address that variability by linking the evidence expected at ethics review to two features of an investigation: the device’s risk class and its stage of development. The stated aim is not to impose identical requirements on every study, but to establish a proportional approach. Study teams can use the reference while planning their evidence, while sponsors and manufacturers can prepare more complete applications. Reviewers gain an internationally informed framework against which to assess submissions.

Fiona Loke, Director of the Medical Technology Office at SingHealth and the working group convener, said the participants sought international best practices and drew on industry, public and private healthcare providers, and experts in regulation and ethics review. “Innovators preparing to undergo an ethics review for their medical device study can now prepare their submissions using a common reference, based on their device’s risk class and study stage,” she said.

Professor John Lim, Executive Director of the Centre of Regulatory Excellence at Duke-NUS Medical School, said the reference consolidates what regulators, ethics committees, clinicians and industry had learned about conducting device studies well. He said TR 151 is applicable from the earliest planning stages and is intended to support trust in clinical evidence generated in Singapore and help innovators bring safe, effective devices to patients with greater confidence.

Lee Suen Ming, Chair of the Biomedical and Health Standards Committee, encouraged the healthcare community to adopt the reference. “Singapore’s medtech ecosystem is producing more homegrown devices that must be tested in patients for the first time. TR 151 provides hospitals, ethics committees and companies with common guidance for conducting these investigations,” he said. He said broader adoption could improve the quality and consistency of submissions while safeguarding participant safety.

The initiative is aimed specifically at investigational medical devices, defined in the announcement as devices that remain experimental for their intended use. It is a procedural standard for preparing and reviewing clinical investigations rather than evidence that any particular device is safe or effective, and the announcement does not report results from patient studies. Its anticipated effects are more predictable ethics review, clearer planning for developers and sponsors, and a more consistent basis for assessing submissions. Both TR 151:2026 and the Singapore adoption of ISO 14155:2026 were made available for purchase through the Singapore Standards eShop.

Subject of Research: A national technical reference for clinical investigations of investigational medical devices in Singapore

Article Title: Singapore launches national reference to guide clinical investigations of medical devices

Article References: Singapore launches national reference to guide clinical investigations of medical devices. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: medical devices, clinical investigations, ethics review, regulatory standards, ISO 14155, Singapore, risk management, research ethics, healthcare innovation, launches, national, reference

Funded by the European Commission and coordinated by Radboud University, the cornerstone project NatureRestoreR: guiding nature restoration through integrated ecological modelling was officially launched on 1 September 2026. The project carries grant number 101287178 and will be implemented over a four-year period, concluding on 1 September 2030. The primary objective of NatureRestoreR is to provide publicly available ecological modelling tools and guidelines. These resources are intended to enable national and regional authorities to design restoration plans based on a scientifically sound understanding of how species, habitats, and ecosystem services respond to restoration measures in different places and under evolving climate dynamics.

A critical challenge in guiding ecosystem restoration efforts is that there is no single approach to restoring nature. Species and habitats may respond differently to a given restoration measure depending on local environmental conditions. Furthermore, climate change can affect the long-term outcomes of restoration efforts. Consequently, authorities need robust scientific evidence to understand how species and ecosystems are likely to respond to restoration under specific circumstances. They also need to identify where interventions can create synergies or trade-offs. NatureRestoreR seeks to address this challenge by convening existing data, scientific knowledge, and modelling approaches to develop an innovative suite of adaptive and easy-to-use ecological modelling tools.

These modelling tools will enable evidence-based prospective assessment of restoration measures. Specifically, they will model the potential impacts on species’ habitats, the extent and condition of habitats protected under the EU Nature Directives, and the provision of ecosystem services. By providing these insights, the project aims to help decision-makers make more informed choices about where and how to allocate restoration resources. This approach is designed to ensure that restoration efforts are not only ecologically sound but also practically feasible for national and regional authorities.

The development of these modelling tools will be a collaborative effort, co-developed and tested through a co-creation process involving researchers and implementation partners. The project will use information from the initial and final revised National Restoration Plans of five EU Member States: Austria, Italy, France, Estonia, and the Netherlands. This collaborative approach will enable the project partners to assess how these plans contribute to the objective of the EU Biodiversity Strategy and the Nature Restoration Regulation. By working with these specific national plans, the project ensures that the tools are relevant to real-world policy contexts and can be adapted to different national circumstances.

Reflecting on the project’s long-term vision, Aafke Schipper, a member of the coordination team at Radboud University, emphasized the importance of the partnership structure. Schipper noted that NatureRestoreR relies on a unique co-creation partnership between ecological researchers and national authorities responsible for or involved in the implementation of the Nature Restoration Regulation. Through this partnership, the project ensures that it meets the needs of decision-makers and practitioners who are implementing and monitoring the regulation. This focus on user needs is central to the project’s design, aiming to create tools that are not only scientifically rigorous but also practical for those on the ground.

NatureRestoreR’s transdisciplinary partnership brings together ecological modelling experts and national agencies with deep knowledge of the EU Nature Directives and National Restoration Plans. Working together, these partners aim to strengthen the relation between ecological knowledge and the decisions shaping Europe’s landscape. The project recognizes that effective restoration requires a close link between scientific understanding and policy implementation. By integrating these two areas, NatureRestoreR hopes to create a more cohesive approach to ecosystem restoration across the continent. This integration is seen as essential for achieving the ambitious targets set by the EU.

Throughout the project, NatureRestoreR will engage with researchers, practitioners, policymakers, and other stakeholders interested in advancing effective, evidence-informed ecosystem restoration across Europe. This broad engagement is intended to ensure that the project’s outputs are widely accessible and useful to a diverse range of actors involved in nature restoration. The project team encourages stakeholders to follow NatureRestoreR on LinkedIn to stay up to date with the project’s latest news, activities, and results. This ongoing communication is part of the project’s strategy to build a community of practice around evidence-based restoration.

The launch of NatureRestoreR represents a significant step forward in the effort to make nature restoration smarter and more effective in Europe. By providing the tools and evidence needed to design and refine restoration plans, the project aims to support the implementation of the EU Nature Restoration Regulation. The focus on co-creation and transdisciplinary collaboration is expected to ensure that the project’s outputs are relevant and useful to those responsible for implementing restoration measures. As the project progresses over the next four years, it will provide valuable insights into how ecological modelling can be used to guide restoration efforts in a changing climate. The ultimate goal is to contribute to the restoration of Europe’s ecosystems and the achievement of the EU’s biodiversity targets.

Subject of Research: Environmental Policy and Ecology

Article Title: NatureRestoreR launches to support Europe in making nature restoration smarter and more effective

Article References: NatureRestoreR launches to support Europe in making nature restoration smarter and more effective. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Nature Restoration, EU Policy, Ecological Modelling, Biodiversity, Climate Change, Radboud University, European Commission, NatureRestoreR, launches, support, Europe, making